Literature DB >> 16937488

Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term.

Jeremy R Jass1.   

Abstract

The term Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is a poor descriptor of the syndrome described by Lynch. Over the last decade, the term has been applied to heterogeneous groups of families meeting limited clinical criteria, for example the Amsterdam criteria. It is now apparent that not all Amsterdam criteria-positive families have the Lynch syndrome. The term HNPCC has also been applied to clinical scenarios in which CRCs with DNA microsatellite instability are diagnosed but in which there is no vertical transmission of an altered DNA mismatch repair (MMR) gene. A term that has multiple, mutually incompatible meanings is highly problematic, particularly when it may influence the management of an individual family. The Lynch syndrome is best understood as a hereditary predisposition to malignancy that is explained by a germline mutation in a DNA MMR gene. The diagnosis does not depend in an absolute sense on any particular family pedigree structure or age of onset of malignancy. Families with a strong family history of colorectal cancer that do not have Lynch syndrome have been grouped as 'Familial Colorectal Cancer Type-X'. The first step in characterizing these cancer families is to distinguish them from Lynch syndrome. The term HNPCC no longer serves any useful purpose and should be phased out.

Entities:  

Mesh:

Year:  2006        PMID: 16937488      PMCID: PMC4087395          DOI: 10.3748/wjg.v12.i31.4943

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  69 in total

Review 1.  Mismatch repair, molecular switches, and signal transduction.

Authors:  R Fishel
Journal:  Genes Dev       Date:  1998-07-15       Impact factor: 11.361

2.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines.

Authors:  M A Rodriguez-Bigas; C R Boland; S R Hamilton; D E Henson; J R Jass; P M Khan; H Lynch; M Perucho; T Smyrk; L Sobin; S Srivastava
Journal:  J Natl Cancer Inst       Date:  1997-12-03       Impact factor: 13.506

3.  HNPCC associated with germline mutation in the TGF-beta type II receptor gene.

Authors:  S L Lu; M Kawabata; T Imamura; Y Akiyama; T Nomizu; K Miyazono; Y Yuasa
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

Review 4.  Phenotype associated with recessively inherited mutations in DNA mismatch repair (MMR) genes.

Authors:  M de Vos; B Hayward; D T Bonthron; E Sheridan
Journal:  Biochem Soc Trans       Date:  2005-08       Impact factor: 5.407

5.  A homozygous mutation in MSH6 causes Turcot syndrome.

Authors:  Madhuri R Hegde; Belinda Chong; Maria E Blazo; Lip Hon E Chin; Patricia A Ward; Murali M Chintagumpala; John Y Kim; Sharon E Plon; C Sue Richards
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

Review 6.  Evolution of the nomenclature for the hereditary colorectal cancer syndromes.

Authors:  C Richard Boland
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer.

Authors:  Daniel L Worthley; Michael D Walsh; Melissa Barker; Andrew Ruszkiewicz; Graeme Bennett; Kerry Phillips; Graeme Suthers
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

8.  Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer.

Authors:  B V Bapat; L Madlensky; L K Temple; T Hiruki; M Redston; D L Baron; L Xia; V A Marcus; C Soravia; A Mitri; W Shen; R Gryfe; T Berk; B N Chodirker; Z Cohen; S Gallinger
Journal:  Hum Genet       Date:  1999-02       Impact factor: 4.132

9.  Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis.

Authors:  J R Jass; D S Cottier; V Pokos; S Parry; I M Winship
Journal:  Pathology       Date:  1997-02       Impact factor: 5.306

10.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

Authors:  Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

View more
  46 in total

1.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

2.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

Review 3.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

4.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 5.  Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome.

Authors:  Noralane M Lindor
Journal:  Surg Oncol Clin N Am       Date:  2009-10       Impact factor: 3.495

6.  Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.

Authors:  Hanifa Bouzourene; Pierre Hutter; Lorena Losi; Patricia Martin; Jean Benhattar
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 7.  Lynch syndrome: clinical, pathological, and genetic insights.

Authors:  Ralph Schneider; Claudia Schneider; Matthias Kloor; Alois Fürst; Gabriela Möslein
Journal:  Langenbecks Arch Surg       Date:  2012-02-24       Impact factor: 3.445

Review 8.  Signs and genetics of rare cancer syndromes with gastroenterological features.

Authors:  William Bruno; Giuseppe Fornarini; Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

9.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

10.  Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial.

Authors:  L I Overbeek; R P Hermens; J H van Krieken; E M Adang; M Casparie; F M Nagengast; M J Ligtenberg; N Hoogerbrugge
Journal:  Virchows Arch       Date:  2010-04-09       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.